Magnetic Separation and Concentration of Aβ 1-42 Molecules Dispersed at the Threshold Concentration for Alzheimer's Disease Diagnosis in Clinically-relevant Volumes of Sample

Overview

Journal J Nanobiotechnology

Publisher Biomed Central

Specialty Biotechnology

Date 2023 Sep 14

PMID 37710290

Authors

Alessandro Surpi

Mauro Murgia

Sonia Lopez-Amoedo

Manuel A Gonzalez-Gomez

Yolanda Pineiro

Jose Rivas

Valeria Perugini

Matteo Santin

Tomas Sobrino

Pierpaolo Greco

Francisco Campos

Valentin Alek Dediu

Affiliations

Soon will be listed here.

Abstract

Background: Alzheimer's disease (AD) is the leading cause of dementia and loss of autonomy in the elderly, implying a progressive cognitive decline and limitation of social activities. The progressive aging of the population is expected to exacerbate this problem in the next decades. Therefore, there is an urgent need to develop quantitative diagnostic methodologies to assess the onset the disease and its progression especially in the initial phases.

Results: Here we describe a novel technology to extract one of the most important molecular biomarkers of AD (Aβ) from a clinically-relevant volume - 100 µl - therein dispersed in a range of concentrations critical for AD early diagnosis. We demonstrate that it is possible to immunocapture Aβ on 20 nm wide magnetic nanoparticles functionalized with hyperbranced KVLFF aptamers. Then, it is possible to transport them through microfluidic environments to a detection system where virtually all (~ 90%) the Aβ molecules are concentrated in a dense plug of ca.50 nl. The technology is based on magnetic actuation by permanent magnets, specifically designed to generate high gradient magnetic fields. These fields, applied through submillimeter-wide channels, can concentrate, and confine magnetic nanoparticles (MNPs) into a droplet with an optimized shape that maximizes the probability of capturing highly diluted molecular biomarkers. These advancements are expected to provide efficient protocols for the concentration and manipulation of molecular biomarkers from clinical samples, enhancing the accuracy and the sensitivity of diagnostic technologies.

Conclusions: This easy to automate technology allows an efficient separation of AD molecular biomarkers from volumes of biological solutions complying with the current clinical protocols and, ultimately, leads to accurate measurements of biomarkers. The technology paves a new way for a quantitative AD diagnosis at the earliest stage and it is also adaptable for the biomarker analysis of other pathologies.

References

Blennow K, Mattsson N, Scholl M, Hansson O, Zetterberg H . Amyloid biomarkers in Alzheimer's disease. Trends Pharmacol Sci. 2015; 36(5):297-309. DOI: 10.1016/j.tips.2015.03.002. View

Surpi A, Shelyakova T, Murgia M, Rivas J, Pineiro Y, Greco P . Versatile magnetic configuration for the control and manipulation of superparamagnetic nanoparticles. Sci Rep. 2023; 13(1):5301. PMC: 10066313. DOI: 10.1038/s41598-023-32299-9. View

Gobom J, Parnetti L, Rosa-Neto P, Vyhnalek M, Gauthier S, Cataldi S . Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid. Clin Chem Lab Med. 2021; 60(2):207-219. DOI: 10.1515/cclm-2021-0651. View

Leitao M, Silva-Spinola A, Santana I, Olmedo V, Nadal A, Le Bastard N . Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer's disease. Alzheimers Res Ther. 2019; 11(1):91. PMC: 6875031. DOI: 10.1186/s13195-019-0550-8. View

Fagan A, Mintun M, Mach R, Lee S, Dence C, Shah A . Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol. 2005; 59(3):512-9. DOI: 10.1002/ana.20730. View

Jack Jr C, Knopman D, Jagust W, Petersen R, Weiner M, Aisen P . Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013; 12(2):207-16. PMC: 3622225. DOI: 10.1016/S1474-4422(12)70291-0. View

Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chetelat G, Teunissen C . Alzheimer's disease. Lancet. 2021; 397(10284):1577-1590. PMC: 8354300. DOI: 10.1016/S0140-6736(20)32205-4. View

Mattsson N, Andreasson U, Persson S, Carrillo M, Collins S, Chalbot S . CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimers Dement. 2013; 9(3):251-61. PMC: 3707386. DOI: 10.1016/j.jalz.2013.01.010. View

Ramadan Q, Gijs M . Simultaneous sample washing and concentration using a "trapping-and-releasing" mechanism of magnetic beads on a microfluidic chip. Analyst. 2011; 136(6):1157-66. DOI: 10.1039/c0an00654h. View

10.

Wu K, Su D, Liu J, Saha R, Wang J . Magnetic nanoparticles in nanomedicine: a review of recent advances. Nanotechnology. 2019; 30(50):502003. DOI: 10.1088/1361-6528/ab4241. View

11.

Donolato M, Vavassori P, Gobbi M, Deryabina M, Hansen M, Metlushko V . On-chip manipulation of protein-coated magnetic beads via domain-wall conduits. Adv Mater. 2010; 22(24):2706-10. DOI: 10.1002/adma.201000146. View

12.

Saei A, Asfia S, Kouchakzadeh H, Rahmandoust M . Antibody-modified magnetic nanoparticles as specific high-efficient cell-separation agents. J Biomed Mater Res B Appl Biomater. 2020; 108(6):2633-2642. DOI: 10.1002/jbm.b.34595. View

13.

Cohen A, Landau S, Snitz B, Klunk W, Blennow K, Zetterberg H . Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease. Mol Cell Neurosci. 2018; 97:3-17. DOI: 10.1016/j.mcn.2018.12.004. View

14.

Johansson L, Gunnarsson K, Bijelovic S, Eriksson K, Surpi A, Gothelid E . A magnetic microchip for controlled transport of attomole levels of proteins. Lab Chip. 2010; 10(5):654-61. DOI: 10.1039/b919893h. View

15.

Willemse E, Tijms B, van Berckel B, Le Bastard N, van der Flier W, Scheltens P . Comparing CSF amyloid-beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status. Alzheimers Dement (Amst). 2021; 13(1):e12182. PMC: 8088096. DOI: 10.1002/dad2.12182. View

16.

Blumler P . Magnetic Guiding with Permanent Magnets: Concept, Realization and Applications to Nanoparticles and Cells. Cells. 2021; 10(10). PMC: 8535073. DOI: 10.3390/cells10102708. View

17.

Cui H, Song W, Ru X, Fu W, Ji L, Zhou W . A simplified viral RNA extraction method based on magnetic nanoparticles for fast and high-throughput detection of SARS-CoV-2. Talanta. 2023; 258:124479. PMC: 10035799. DOI: 10.1016/j.talanta.2023.124479. View

18.

Nguyen N, Taverna M, Smadja C, Mai T . Recent Electrokinetic and Microfluidic Strategies for Detection of Amyloid Beta Peptide Biomarkers: Towards Molecular Diagnosis of Alzheimer's Disease. Chem Rec. 2020; 21(1):149-161. DOI: 10.1002/tcr.202000103. View

19.

Gonzalez-Gomez M, Belderbos S, Yanez-Vilar S, Pineiro Y, Cleeren F, Bormans G . Development of Superparamagnetic Nanoparticles Coated with Polyacrylic Acid and Aluminum Hydroxide as an Efficient Contrast Agent for Multimodal Imaging. Nanomaterials (Basel). 2019; 9(11). PMC: 6915788. DOI: 10.3390/nano9111626. View

20.

Tang C, He Z, Liu H, Xu Y, Huang H, Yang G . Application of magnetic nanoparticles in nucleic acid detection. J Nanobiotechnology. 2020; 18(1):62. PMC: 7171821. DOI: 10.1186/s12951-020-00613-6. View